{"nct_id":"NCT06525220","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","status":"RECRUITING","status_verified_date":"2025-03","start_date":"2024-09-25","start_date_type":"ACTUAL","primary_completion_date":"2028-01","primary_completion_date_type":"ESTIMATED","completion_date":"2030-07","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRUS"]}